178 related articles for article (PubMed ID: 35809111)
1. Incidence of Post-denosumab Rebound Hypercalcaemia in Bony-Metastatic Breast Cancer.
Wang R; Rajanayagam S; Ngan J; Renouf DA
Calcif Tissue Int; 2022 Oct; 111(4):391-395. PubMed ID: 35809111
[TBL] [Abstract][Full Text] [Related]
2. Rebound hypercalcemia post-denosumab cessation in metastatic breast cancer.
Wang R; Renouf DA
Osteoporos Int; 2022 Jul; 33(7):1625-1629. PubMed ID: 35286436
[TBL] [Abstract][Full Text] [Related]
3. Denosumab for central giant cell granuloma in an Australian tertiary paediatric centre.
Vanderniet JA; Wall CL; Mullins A; London K; Lim L; Hibbert S; Briody J; Padhye B; Poon M; Biggin A; Dalla-Pozza L; Munns CF
Bone; 2022 Jun; 159():116395. PubMed ID: 35331976
[TBL] [Abstract][Full Text] [Related]
4. A systematic review of the role of bisphosphonates in metastatic disease.
Ross JR; Saunders Y; Edmonds PM; Patel S; Wonderling D; Normand C; Broadley K
Health Technol Assess; 2004; 8(4):1-176. PubMed ID: 14960258
[TBL] [Abstract][Full Text] [Related]
5. Bisphosphonates and other bone agents for breast cancer.
Wong MH; Stockler MR; Pavlakis N
Cochrane Database Syst Rev; 2012 Feb; (2):CD003474. PubMed ID: 22336790
[TBL] [Abstract][Full Text] [Related]
6. Bisphosphonates for breast cancer.
Pavlakis N; Schmidt R; Stockler M
Cochrane Database Syst Rev; 2005 Jul; (3):CD003474. PubMed ID: 16034900
[TBL] [Abstract][Full Text] [Related]
7. Incidence of osteonecrosis of the jaw in patients with bone metastases treated sequentially with bisphosphonates and denosumab.
Loyson T; Van Cann T; Schöffski P; Clement PM; Bechter O; Spriet I; Coropciuc R; Politis C; Vandeweyer RO; Schoenaers J; Dumez H; Berteloot P; Neven P; Nackaerts K; Woei-A-Jin FJSH; Punie K; Wildiers H; Beuselinck B
Acta Clin Belg; 2018 Apr; 73(2):100-109. PubMed ID: 28693379
[TBL] [Abstract][Full Text] [Related]
8. Surgical Management and Denosumab for Aneurysmal Bone Cysts of the Spine in an Australian Tertiary Paediatric Centre.
Vanderniet JA; Tsinas D; Wall CL; Girgis CM; London K; Keane C; Briody J; Hibbert S; Poon M; Padhye B; Biggin A; Dalla-Pozza L; Gray RJ; Munns CF
Calcif Tissue Int; 2023 May; 112(5):592-602. PubMed ID: 36810677
[TBL] [Abstract][Full Text] [Related]
9. The role of denosumab in the prevention of hypercalcaemia of malignancy in cancer patients with metastatic bone disease.
Diel IJ; Body JJ; Stopeck AT; Vadhan-Raj S; Spencer A; Steger G; von Moos R; Goldwasser F; Feng A; Braun A
Eur J Cancer; 2015 Jul; 51(11):1467-75. PubMed ID: 25976743
[TBL] [Abstract][Full Text] [Related]
10. Effect of antiresorptive drugs on bony turnover in the jaw: denosumab compared with bisphosphonates.
Ristow O; Gerngroß C; Schwaiger M; Hohlweg-Majert B; Kehl V; Jansen H; Hahnefeld L; Koerdt S; Otto S; Pautke C
Br J Oral Maxillofac Surg; 2014 Apr; 52(4):308-13. PubMed ID: 24582013
[TBL] [Abstract][Full Text] [Related]
11. Severe hypercalcemia following denosumab treatment in a juvenile patient.
Setsu N; Kobayashi E; Asano N; Yasui N; Kawamoto H; Kawai A; Horiuchi K
J Bone Miner Metab; 2016 Jan; 34(1):118-22. PubMed ID: 26056018
[TBL] [Abstract][Full Text] [Related]
12. Osteonecrosis of the Jaw and Rebound Hypercalcemia in Young People Treated With Denosumab for Giant Cell Tumor of Bone.
Uday S; Gaston CL; Rogers L; Parry M; Joffe J; Pearson J; Sutton D; Grimer R; Högler W
J Clin Endocrinol Metab; 2018 Feb; 103(2):596-603. PubMed ID: 29211870
[TBL] [Abstract][Full Text] [Related]
13. Antiresorptive agents' bone-protective and adjuvant effects in postmenopausal women with early breast cancer.
Chukir T; Liu Y; Farooki A
Br J Clin Pharmacol; 2019 Jun; 85(6):1125-1135. PubMed ID: 30536446
[TBL] [Abstract][Full Text] [Related]
14. Extended efficacy and safety of denosumab in breast cancer patients with bone metastases not receiving prior bisphosphonate therapy.
Lipton A; Steger GG; Figueroa J; Alvarado C; Solal-Celigny P; Body JJ; de Boer R; Berardi R; Gascon P; Tonkin KS; Coleman RE; Paterson AH; Gao GM; Kinsey AC; Peterson MC; Jun S
Clin Cancer Res; 2008 Oct; 14(20):6690-6. PubMed ID: 18927312
[TBL] [Abstract][Full Text] [Related]
15. Sixty spontaneous vertebral fractures after denosumab discontinuation in 15 women with early-stage breast cancer under aromatase inhibitors.
Gonzalez-Rodriguez E; Aubry-Rozier B; Stoll D; Zaman K; Lamy O
Breast Cancer Res Treat; 2020 Jan; 179(1):153-159. PubMed ID: 31598815
[TBL] [Abstract][Full Text] [Related]
16. Incidence of osteonecrosis of the jaw by the use of osteoclast inhibitors in patients with bone metastases: a retrospective cohort study.
Chaurand-Lara J; Pacheco-Ruiz L; Trejo-Campos JL; Facio-Umaña JA; Mora-Pérez J
Cir Cir; 2019; 87(4):396-401. PubMed ID: 31264983
[TBL] [Abstract][Full Text] [Related]
17. Hypocalcaemia in patients with metastatic bone disease treated with denosumab.
Body JJ; Bone HG; de Boer RH; Stopeck A; Van Poznak C; Damião R; Fizazi K; Henry DH; Ibrahim T; Lipton A; Saad F; Shore N; Takano T; Shaywitz AJ; Wang H; Bracco OL; Braun A; Kostenuik PJ
Eur J Cancer; 2015 Sep; 51(13):1812-21. PubMed ID: 26093811
[TBL] [Abstract][Full Text] [Related]
18. Atypical femoral fracture after receiving antiresorptive drugs in breast cancer patients with bone metastasis.
Ota S; Inoue R; Shiozaki T; Yamamoto Y; Hashimoto N; Takeda O; Yoshikawa K; Ito J; Ishibashi Y
Breast Cancer; 2017 Jul; 24(4):601-607. PubMed ID: 27943163
[TBL] [Abstract][Full Text] [Related]
19. Effect of denosumab versus zoledronic acid on calcium levels in cancer patients with bone metastasis: A retrospective cohort study.
Nasser SM; Sahal A; Hamad A; Elazzazy S
J Oncol Pharm Pract; 2019 Dec; 25(8):1846-1852. PubMed ID: 31694497
[TBL] [Abstract][Full Text] [Related]
20. Zoledronic acid: a review of its use in the management of bone metastases and hypercalcaemia of malignancy.
Wellington K; Goa KL
Drugs; 2003; 63(4):417-37. PubMed ID: 12558465
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]